STOCKHOLM--(BUSINESS WIRE)--Cantargia AB (”Cantargia”) (STO:CANTA) Year-end report for January – December 2015 is available on the company web-site (www.cantargia.com). An extract from the report is presented below.
Significant events in the fourth quarter
· European Patent Office (EPO) issued an officially approved patent for IL1RAP as target molecule for antibody therapy and leukemia diagnostics.
